This clinical trial is focused on studying Type 1 Diabetes, a condition where the body’s immune system attacks the insulin-producing cells in the pancreas. The study will use a medication called Verapamil, which is a type of drug known as a calcium-channel blocker, and another substance called Exenatide, which is a protein-based medication. The purpose of the study is to explore how these treatments affect the mass of beta cells in the pancreas, which are responsible for producing insulin.

Participants in the study will undergo a special imaging process called PET/CT to measure how much of a substance called 68Ga-NODAGA-exendin is taken up by the pancreas. This will help researchers see the differences in beta cell mass before and after treatment, as well as compare results between those receiving the treatment and those receiving a placebo. The study will track these changes over a period of time to understand the effects of the treatments on the pancreas.

The study will involve regular imaging sessions to monitor changes in the pancreas, and these will be compared with other measurements related to insulin production, such as C-peptide and proinsulin levels. The goal is to gain insights into how these treatments might help preserve or improve the function of insulin-producing cells in people with Type 1 Diabetes.